Microsatellite Instability (MSI), HNPCC/Lynch Syndrome
Microsatellite instability is used as an aid in the diagnosis of Hereditary Nonpolyposis Colorectal Cancer (HNPCC) also know as Lynch syndrome. Microsatellites are also known as short tandem repeats found in human DNA as a regulatory and structural part of the human genome. These microsatellites are not longer than 2-6 base pairs in length found in 10-50 repeats. The regions of microsatellite instability are susceptible to mistakes during DNA replication that are typically repaired by mismatch repair proteins (MMR).
Mutation in MMR genes results in nonfunctional MMR proteins, which often results in accumulation of non-repaired, damaged mutated short tandem repeats leading to microsatellite instability (MSI). There are several MMR genes that are prone to mutations. The most common MMR are hMLH1, hMSH2, hPMS1, and hPMS2. Mutations on any of these genes or more than one gene can lead to MSI.
MSI is predominantly associated with polyposis and nonpolyposis colorectal cancer, especially with HNPCC. Hereditary nonpolyposis colorectal cancer (HNPCC) can be a component of Lynch syndrome. It is an autosomal dominant syndrome with early onset of colonic carcinoma and with increased risk for malignancy. Genetic testing for MMRs can confirm the diagnosis of HPNCC and can also identify presymptomatic individuals at risk among the patient's relatives. This test usually covers most common gene mutations (coding regions) in hMLH1, hMSH2, hPMS1, and hPMS2. Early screening can help in patients with family history of colorectal cancer.
- In evaluation for hereditary nonpolyposis type colon cancer (HNPCC)
- Screening for MSI or MMR gene mutation in patients with family history of colon cancer
- Differential diagnosis of colon cancer type
- Therapy and disease management
- Evaluation of family members
- Guiding preventative measures
Mutations of genes in hMLH1, hMSH2, hPMS1, and hPMS2 (one or more) are present in individuals with HNPCC >30-40% : MSI-H phenotype
Increased in:
- Colorectal cancer, some
- Endometrial cancer, some
- Ovarian Cancer, some
- Stomach Cancer, some
Decreased in:
- Tumors associated with MSH6 mutations.
Negative for mutations analyzed
Real Time PCR, PCR with Allele Specific Primer Extension, Pyrosequencing, Chip array, Immunohistochemistry, conventional sequencing, next generation sequencing (NGS).
Tissue & Whole Blood EDTA (Lavender) or ACD (Yellow).
Stability
- Ambient: 3-5 days
- Refrigerated: 5-7 days
1-2 weeks.
| ICD10 Code and Description | LCD Code | NCD Code |
|---|---|---|
| No results found matching your search criteria. | ||
| ICD10 Code and Description | LCD Code | NCD Code |
|---|---|---|
| No results found matching your search criteria. | ||
- Ann Surg Oncol. 2011 Aug 31. [PMID: 21879275]
- World J Gastroenterol. 2006 Oct 7;12(37):5932-40. [PMID: 17009390]
- Dig Dis Sci. 2005 Feb;50(2):336-44. [PMID: 15745097]
- Ann Surg. 1978; 188(6):716-20. [PMID: 736649]
- Dis Markers. 2004;20(4-5):269-76. [PMID: 15528792]
- Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3389-93. [PMID: 16740762]
- Evid Rep Technol Assess (Full Rep). 2007 May;(150):1-180. [PMID: 17764220]
- J Med Genet. 2002; 39(5):323-7. [PMID: 12011148]